Clair Health Inc.

Based in the US, Clair Health Inc. is a health technology company dedicated to advancing women's wellness through innovative hormone monitoring solutions. Based in California, US, founded in 2025 by its co-founders Jenny Duan and Abhinav Agarwal, Clair Health Inc. is focused on developing wearable continuous hormone monitors that allow users to track key hormones in real-time.

In June 2026, Clair Health Inc. raised USD 11. 6 million in seed funding led by new investor Khosla Ventures, with participation from other investors AGI House Ventures, Andreessen Horowitz, Treehub, Brydge Capital, Cartan Capital, and Insiders Ventures. Jenny Duan is currently serving the role of CEO.

Clair Health is focused on developing the first wearable continuous hormone monitor, which enables users to track key hormones such as estrogen, progesterone, luteinizing hormone (LH), follicle-stimulating hormone (FSH), and pregnanediol glucuronide (PdG) in real-time. This innovative device employs a multi-modal sensor array that captures over 130 biomarkers related to physiological changes, providing personalized health insights aimed at enhancing women's wellness. Users can optimize their training, recovery, and daily activities by aligning them with their menstrual cycle, thus addressing specific health concerns such as fertility planning, hormonal health, and navigating perimenopause and menopause. The product is primarily marketed to women of various life stages and is sold directly to consumers through the company’s platform.

Clair Health is targeting geographical markets including North America and Europe, where there is an increasing demand for advanced health monitoring technologies tailored for women's health. Clair Health generates revenue through direct-to-consumer sales of its flagship product, the continuous hormone monitor. Customers have the option to purchase a Founding Membership, which provides them with exclusive benefits such as a 20% discount off the manufacturer's suggested retail price (MSRP) and six months of complimentary access to the Clair Pro subscription. This subscription offers enhanced features and community engagement opportunities.

The company positions itself in a subscription-based model that not only includes the initial device purchase but also ongoing services provided through the app, which consolidates hormone tracking with wellness data. Transactions are structured around individual sales of the device, along with the potential for future subscription renewals, enabling a recurring revenue stream as customers continue to engage with the Clair Health ecosystem. The company will use the June 2026 funding to develop its wearable device, improve its data models, and prepare it for market launch.